Home » Newsletters » BioWorld Science

BioWorld Science

March 29, 2021

View Archived Issues

PepGen develops enhanced delivery oligonucleotides for muscular dystrophy

Albireo initiates dosing in key clinical studies with two of its candidates

Phase I study of intranasal adenovirus vector COVID-19 vaccine candidate, BBV-154

Cholesterol-independent heart disease risk gene

Ultrarare variants give insights into schizophrenia

T-cell 'auto-aggression' causes liver damage in NASH

Engineered myeloid cells prevent pro-metastatic microenvironments

Israeli startup goes bio(me)-prospecting in wild animals

University of Oxford to launch a phase I study evaluating nasally administered ChAdOx1 nCoV-19

Intensity Therapeutics to conduct phase II study of INT230-6 in early-stage breast cancer

AHR as novel therapeutic target for polycystic ovary syndrome

CC-90011 plus EP/EC shows safety in first-line extensive-stage SCLC

LINC00926 identified as a prognostic marker in lung adenocarcinoma

Foresee begins phase II/III study of FP-025 in COVID-19-associated ARDS

Phase II/III study of arimoclomol in inclusion body myositis misses endpoints

Researchers develop a Cyp17-overexpressing murine model of PCOS

Universtiy of Zurich, ETHZ patent bispecific binding agents targeting CD117 and CD3

HMPL-306 enters international phase I studies in solid tumors and hematological malignancies

Jiangsu Chia Tai Tianqing Pharmaceutical Group and collaborators describe GTPase KRAS inhibitors

Shanghai Institute of Materia Medica identifies new AXL and/or MET inhibitors

New ATX inhibitors identified by Humanwell Healthcare, collaborators

Phase IIb/III study of Zyesami for respiratory failure in critical COVID-19 meets primary endpoint

Wigen Biomedicine Technology discovers Wee1hu inhibitors

FDA approves Abecma for relapsed or refractory multiple myeloma

Phase Ib interim data on CDX-0159 for antihistamine-refractory chronic inducible urticaria

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026